Diabetes Treatment (cont.)
Robert Ferry Jr., MD
Robert Ferry Jr., MD
Robert Ferry Jr., MD, is a U.S. board-certified Pediatric Endocrinologist. After taking his baccalaureate degree from Yale College, receiving his doctoral degree and residency training in pediatrics at University of Texas Health Science Center at San Antonio (UTHSCSA), he completed fellowship training in pediatric endocrinology at The Children's Hospital of Philadelphia.
Melissa Conrad Stöppler, MD
Melissa Conrad Stöppler, MD
Melissa Conrad Stöppler, MD, is a U.S. board-certified Anatomic Pathologist with subspecialty training in the fields of Experimental and Molecular Pathology. Dr. Stöppler's educational background includes a BA with Highest Distinction from the University of Virginia and an MD from the University of North Carolina. She completed residency training in Anatomic Pathology at Georgetown University followed by subspecialty fellowship training in molecular diagnostics and experimental pathology.
In this Article
Pramlintide (Symlin) was the first in a class of injectable, anti-hyperglycemic medications for use in addition to insulin for type 1 diabetes or type 2 diabetes. Pramlintide, the active ingredient in Symlin, is a synthetic analog of human amylin, a naturally occurring neuroendocrine hormone synthesized by pancreatic beta-cells that helps control glucose after meals. Similar to insulin, amylin is absent or deficient in person with diabetes. When used with insulin, amylin can improve glycemic control and has additional benefits that cannot be realized with insulin alone.
According to published data, pramlintide reduces post-meal blood sugar peaks, reduces glucose fluctuations throughout the day, enhances satiety (the sensation of fullness) leading to potential weight loss, and lowers mealtime insulin requirements. Pramlintide can improve HbA1c beyond the effect of insulin alone.
Pramlintide is administered by injection just prior to meals (three times each day) for:
Pramlintide warnings and side effects
Pramlintide with insulin has been associated with an increased risk of insulin-induced severe hypoglycemia, particularly in type 1 diabetes. This severe hypoglycemia occurs within 3 hours of injecting pramlintide.
The major side effects of pramlintide are:
Exenatide (Byetta) originated from an interesting source: the saliva of the Gila monster! Scientists observed that this small lizard could go a long time without eating. They discovered a substance in its saliva that slowed stomach emptying, thus making the lizard feel fuller for a longer time. This substance resembled a gut hormone naturally found in humans known as glucagon-like peptide-1 (GLP-1). The enzyme DPP-IV breaks down GLP-If one could make a substance like GLP-1 but that resisted breakdown, it would have potential benefit. Such efforts developed exenatide.
Exenatide is the first in the incretin mimetic class of drugs for type 2 diabetes. Exenatide shares many therapeutic properties with GLP-1, and it mimics natural physiology for self-regulating blood sugar. Namely, exenatide slows stomach emptying and slows the release of glucose from the liver, thereby regulating delivery of nutrients to the intestine for absorption. Exenatide also works centrally in the brain to regulate hunger.
Exenatide is indicated as additional therapy to improve control of blood sugar in type 2 diabetes patients who have not achieved adequate sugar control with metformin, sulfonylurea, or a combination of metformin and sulfonylurea. Exenatide enhances insulin release from the pancreas. Insulin secretion usually increases only when blood sugars are high, then decreases as blood sugar level approaches normal. In addition to enhancing the normal physiology of the pancreatic beta-cell, exenatide suppresses glucose release from the liver, slows stomach emptying, slows absorption of nutrients including carbohydrate, and reduces food intake.
Like pramlintide, exenatide is injected but only twice each day (usually before breakfast and dinner meals). Exenatide is available by a disposable pen form and in two doses. The initial goal is to start a lower dose for a month or so, then move up to the higher dose if needed and as tolerated. Similar to pramlintide, the main side effect of exenatide is nausea, most likely due to its effects on stomach emptying. Exenatide is temperature sensitive, so the initial recommendation was to store pens at 36 F to 46 F (2 C to 8 C). This recommendation recently changed. Unopened pens should be refrigerated; once opened, exenatide pens can be left at room temperature. The risk of hypoglycemia remains a possibility with exenatide, especially when used in combination with sulfonylurea. Your health-care professional may choose to decrease the dose of other medications while initially evaluating your response to exenatide.
Similar to pramlintide, weight reduction is seen with exenatide in most patients. This makes exenatide particularly suitable for the typical type 2 diabetes patient who is also overweight.
FDA is currently considering a longer acting from of exenatide for approval. This new formulation could carry similar benefits and side effects, but with less frequent injections.
Medically Reviewed by a Doctor on 5/7/2015
Viewers share their comments
Diabetes Treatment - Effective Treatments Question: Please describe what treatments have been effective for your diabetes.
Diabetes - Diet Question: Have you found diet, exercise, and medication effective to control your diabetes?
Diabetes Treatment - Medications Question: Please discuss the medications you take to manage your diabetes.
Diabetes Treatment - Insulin Pump Question: Do you use an insulin pump to treat your diabetes? Please describe the pros and cons of this type of treatment.
Diabetes Treatment - Insulin Pens Question: Describe how you use pre-filled insulin pens and the environment in which they are most convenient for you.
Diabetes Treatment - Insulin Question: What type of diabetes do you have, and what methods of insulin delivery have worked best for you?